Nifty
Sensex
:
:
16266.15
54326.39
456.75 (2.89%)
1534.16 (2.91%)

Pharmaceuticals & Drugs - Global

Rating :
42/99

BSE: 532321 | NSE: ZYDUSLIFE

356.85
20-May-2022
  • Open
  • High
  • Low
  • Previous Close
  •  345.30
  •  358.80
  •  339.00
  •  338.75
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  7345887
  •  25831.56
  •  668.90
  •  319.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 36,562.97
  • 7.67
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 40,267.17
  • 0.70%
  • 2.19

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 74.88%
  • 0.87%
  • 7.81%
  • FII
  • DII
  • Others
  • 2.53%
  • 12.33%
  • 1.58%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.12
  • 10.00
  • 4.68

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.93
  • 11.92
  • 2.31

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 12.32
  • 7.49
  • 5.00

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 25.97
  • 23.92
  • 24.02

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 5.17
  • 4.00
  • 3.30

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 16.91
  • 15.73
  • 14.33

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 22
Mar 21
Var%
Dec 21
Dec 20
Var%
Sep 21
Sep 20
Var%
Jun 21
Jun 20
Var%
Net Sales
3,863.80
3,670.30
5.27%
3,655.00
3,633.00
0.61%
3,784.80
3,658.90
3.44%
4,025.40
3,514.60
14.53%
Expenses
3,146.10
2,820.80
11.53%
2,902.50
2,866.50
1.26%
2,924.00
2,845.10
2.77%
3,092.40
2,724.10
13.52%
EBITDA
717.70
849.50
-15.52%
752.50
766.50
-1.83%
860.80
813.80
5.78%
933.00
790.50
18.03%
EBIDTM
18.57%
23.15%
20.59%
21.10%
22.74%
22.24%
23.18%
22.49%
Other Income
79.10
-30.40
-
60.80
27.20
123.53%
53.30
27.50
93.82%
31.60
22.50
40.44%
Interest
38.50
23.20
65.95%
31.10
27.10
14.76%
30.10
45.20
-33.41%
27.30
67.70
-59.68%
Depreciation
185.40
175.30
5.76%
183.20
176.20
3.97%
184.80
174.60
5.84%
182.70
172.80
5.73%
PBT
572.90
547.50
4.64%
599.00
590.40
1.46%
603.50
489.50
23.29%
754.60
572.50
31.81%
Tax
109.20
-206.00
-
110.70
104.50
5.93%
100.00
100.00
0.00%
141.50
118.20
19.71%
PAT
463.70
753.50
-38.46%
488.30
485.90
0.49%
503.50
389.50
29.27%
613.10
454.30
34.95%
PATM
12.00%
20.53%
13.36%
13.37%
13.30%
10.65%
15.23%
12.93%
EPS
3.88
6.63
-41.48%
4.89
5.15
-5.05%
29.32
4.62
534.63%
5.73
4.43
29.35%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Net Sales
15,329.00
15,102.20
14,253.10
13,165.60
11,954.50
9,376.50
9,426.80
8,651.30
7,224.00
6,357.70
5,263.30
Net Sales Growth
5.89%
5.96%
8.26%
10.13%
27.49%
-0.53%
8.96%
19.76%
13.63%
20.79%
 
Cost Of Goods Sold
5,600.20
4,472.50
4,243.30
4,141.30
3,656.90
3,065.00
2,673.20
2,814.10
2,412.60
2,036.80
1,464.10
Gross Profit
9,728.80
10,629.70
10,009.80
9,024.30
8,297.60
6,311.50
6,753.60
5,837.20
4,811.40
4,320.90
3,799.20
GP Margin
63.47%
70.39%
70.23%
68.54%
69.41%
67.31%
71.64%
67.47%
66.60%
67.96%
72.18%
Total Expenditure
12,065.00
11,763.60
11,472.90
10,187.20
9,125.90
7,475.00
7,097.30
6,897.40
6,031.20
5,234.00
4,181.50
Power & Fuel Cost
-
234.50
252.90
231.60
211.40
174.50
155.40
145.40
129.70
124.40
93.40
% Of Sales
-
1.55%
1.77%
1.76%
1.77%
1.86%
1.65%
1.68%
1.80%
1.96%
1.77%
Employee Cost
-
2,254.80
2,169.80
1,903.20
1,644.70
1,485.20
1,119.00
1,096.50
974.00
818.40
679.90
% Of Sales
-
14.93%
15.22%
14.46%
13.76%
15.84%
11.87%
12.67%
13.48%
12.87%
12.92%
Manufacturing Exp.
-
2,353.80
2,230.00
1,923.20
1,680.40
955.30
1,397.60
1,136.90
936.50
897.30
718.90
% Of Sales
-
15.59%
15.65%
14.61%
14.06%
10.19%
14.83%
13.14%
12.96%
14.11%
13.66%
General & Admin Exp.
-
385.70
582.60
583.40
398.70
466.00
356.40
326.80
302.70
342.20
272.60
% Of Sales
-
2.55%
4.09%
4.43%
3.34%
4.97%
3.78%
3.78%
4.19%
5.38%
5.18%
Selling & Distn. Exp.
-
1,477.60
1,468.40
1,033.30
1,129.40
826.40
979.60
1,047.20
980.50
857.50
767.40
% Of Sales
-
9.78%
10.30%
7.85%
9.45%
8.81%
10.39%
12.10%
13.57%
13.49%
14.58%
Miscellaneous Exp.
-
584.70
525.90
371.20
404.40
502.60
416.10
330.50
295.20
157.40
767.40
% Of Sales
-
3.87%
3.69%
2.82%
3.38%
5.36%
4.41%
3.82%
4.09%
2.48%
3.52%
EBITDA
3,264.00
3,338.60
2,780.20
2,978.40
2,828.60
1,901.50
2,329.50
1,753.90
1,192.80
1,123.70
1,081.80
EBITDA Margin
21.29%
22.11%
19.51%
22.62%
23.66%
20.28%
24.71%
20.27%
16.51%
17.67%
20.55%
Other Income
224.80
44.90
117.10
208.50
133.00
147.10
116.60
57.20
85.90
38.40
53.00
Interest
127.00
168.80
341.80
195.80
110.80
63.10
52.80
67.90
118.10
168.70
182.70
Depreciation
736.10
724.80
696.50
598.60
538.80
373.30
292.10
287.30
201.20
184.70
157.90
PBT
2,530.00
2,489.90
1,859.00
2,392.50
2,312.00
1,612.20
2,101.20
1,455.90
959.40
808.70
794.20
Tax
461.40
147.20
319.80
530.30
564.40
128.90
177.40
259.40
106.00
118.80
113.00
Tax Rate
18.24%
6.44%
21.39%
22.26%
24.41%
8.00%
8.45%
17.95%
11.25%
14.69%
14.23%
PAT
2,068.60
2,086.20
1,147.80
1,801.90
1,713.00
1,453.90
1,890.90
1,148.50
803.60
653.50
652.60
PAT before Minority Interest
1,937.60
2,137.60
1,175.60
1,851.80
1,747.60
1,483.00
1,921.30
1,186.10
836.20
689.90
681.20
Minority Interest
-131.00
-51.40
-27.80
-49.90
-34.60
-29.10
-30.40
-37.60
-32.60
-36.40
-28.60
PAT Margin
13.49%
13.81%
8.05%
13.69%
14.33%
15.51%
20.06%
13.28%
11.12%
10.28%
12.40%
PAT Growth
-0.70%
81.76%
-36.30%
5.19%
17.82%
-23.11%
64.64%
42.92%
22.97%
0.14%
 
EPS
20.21
20.38
11.21
17.60
16.73
14.20
18.47
11.22
7.85
6.38
6.37

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Shareholder's Funds
12,992.30
10,375.70
10,386.30
8,744.50
6,960.00
5,699.20
4,251.60
3,439.00
2,944.50
2,585.90
Share Capital
102.40
102.40
102.40
102.40
102.40
102.40
102.40
102.40
102.40
102.40
Total Reserves
12,889.90
10,273.30
10,283.90
8,642.10
6,857.60
5,596.80
4,149.20
3,336.60
2,842.10
2,483.50
Non-Current Liabilities
19.40
2,853.90
3,491.10
2,122.20
1,903.30
736.10
1,341.50
1,589.20
1,640.00
1,555.10
Secured Loans
0.00
1,953.60
2,332.80
200.60
319.60
393.80
664.00
851.40
917.20
901.90
Unsecured Loans
609.50
1,261.00
1,616.90
2,354.50
2,148.80
502.60
486.40
510.80
508.80
420.40
Long Term Provisions
309.50
235.20
184.10
155.90
151.20
120.70
90.40
76.10
66.50
75.60
Current Liabilities
7,861.30
8,269.40
7,342.50
6,083.00
5,305.80
3,461.00
3,285.10
2,814.00
2,670.40
2,191.60
Trade Payables
2,205.90
2,044.30
1,922.60
1,888.40
1,547.90
1,308.10
1,090.90
910.80
656.80
545.50
Other Current Liabilities
2,166.20
2,126.30
2,033.60
1,484.90
1,212.10
860.70
628.20
708.10
509.20
730.90
Short Term Borrowings
3,070.90
3,826.50
3,196.90
2,557.50
2,476.90
1,210.90
1,183.50
902.40
1,257.10
687.10
Short Term Provisions
418.30
272.30
189.40
152.20
68.90
81.30
382.50
292.70
247.30
228.10
Total Liabilities
22,810.30
22,833.70
22,512.80
17,140.70
14,325.20
10,032.10
9,047.10
7,986.50
7,374.20
6,423.00
Net Block
12,132.80
12,230.50
12,163.70
6,482.60
5,755.10
3,747.90
3,352.20
3,123.80
3,025.60
2,857.10
Gross Block
17,345.00
16,781.50
15,702.30
9,349.10
8,102.90
5,767.30
5,138.50
4,664.00
4,376.20
3,990.90
Accumulated Depreciation
5,212.20
4,551.00
3,538.60
2,866.50
2,345.80
2,016.80
1,786.30
1,540.20
1,350.60
1,096.00
Non Current Assets
14,094.30
14,118.30
14,014.70
8,911.00
8,302.90
5,751.70
4,820.40
4,548.60
4,182.50
3,610.00
Capital Work in Progress
783.20
741.50
837.20
1,527.20
1,543.30
950.80
797.90
891.50
735.60
483.90
Non Current Investment
631.20
552.20
443.60
470.90
385.70
217.10
33.20
22.20
21.20
21.20
Long Term Loans & Adv.
323.30
332.00
410.40
300.00
384.70
661.20
637.10
511.10
400.10
247.80
Other Non Current Assets
223.80
262.10
159.80
130.30
234.10
174.70
0.00
0.00
0.00
0.00
Current Assets
8,716.00
8,715.40
8,498.10
8,229.70
6,022.30
4,280.40
4,226.70
3,437.90
3,191.70
2,813.00
Current Investments
198.90
212.80
229.90
274.80
49.10
199.10
121.20
64.40
93.30
3.00
Inventories
3,236.20
2,789.00
2,688.00
2,385.30
1,803.70
1,337.10
1,535.70
1,367.50
1,213.60
1,090.50
Sundry Debtors
3,127.30
3,663.20
3,950.80
3,206.30
2,277.50
1,746.60
1,588.40
1,133.70
955.10
920.90
Cash & Bank
888.30
964.90
548.90
1,314.90
1,543.50
638.70
669.90
548.80
583.80
466.60
Other Current Assets
1,265.30
441.60
496.00
520.70
348.50
358.90
311.50
323.50
345.90
332.00
Short Term Loans & Adv.
814.90
643.90
584.50
527.70
268.50
234.80
240.80
254.90
279.00
274.60
Net Current Assets
854.70
446.00
1,155.60
2,146.70
716.50
819.40
941.60
623.90
521.30
621.40
Total Assets
22,810.30
22,833.70
22,512.80
17,140.70
14,325.20
10,032.10
9,047.10
7,986.50
7,374.20
6,423.00

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Cash From Operating Activity
3,293.00
2,931.50
1,281.90
919.30
1,311.70
1,893.50
993.60
902.80
603.40
511.10
PBT
2,284.80
1,495.40
2,382.10
2,312.00
1,611.90
2,098.70
1,445.50
942.20
808.70
794.20
Adjustment
1,166.40
1,474.40
539.10
624.30
333.70
249.80
344.50
269.00
315.90
320.90
Changes in Working Capital
186.80
263.80
-971.70
-1,383.90
-411.20
271.70
-377.00
-20.10
-201.60
-421.70
Cash after chg. in Working capital
3,638.00
3,233.60
1,949.50
1,552.40
1,534.40
2,620.20
1,413.00
1,191.10
923.00
693.40
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-345.00
-302.50
-675.40
-602.30
-237.60
-646.00
-386.90
-172.80
-272.00
-143.50
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.40
7.80
-30.80
14.90
-80.70
-32.50
-115.50
0.00
-38.80
Cash From Investing Activity
-722.50
-1,012.30
-4,238.70
-973.70
-2,871.90
-863.50
-464.70
-438.00
-682.30
-1,199.50
Net Fixed Assets
-462.80
-289.60
-1,652.30
-600.20
-557.40
-531.50
-271.50
-239.50
-646.90
-361.70
Net Investments
-66.50
-2,208.90
-577.10
305.60
-1,606.20
-108.40
-651.40
-277.80
-67.70
-513.40
Others
-193.20
1,486.20
-2,009.30
-679.10
-708.30
-223.60
458.20
79.30
32.30
-324.40
Cash from Financing Activity
-2,548.90
-1,528.20
1,884.60
51.50
2,315.80
-934.80
-351.10
-528.70
285.80
859.80
Net Cash Inflow / Outflow
21.60
391.00
-1,072.20
-2.90
755.60
95.20
177.80
-63.90
206.90
171.40
Opening Cash & Equivalents
1,177.70
778.80
1,589.70
1,592.60
837.00
737.90
612.60
676.50
469.60
295.20
Closing Cash & Equivalent
1,087.20
1,177.70
778.80
1,589.70
1,592.60
837.00
790.40
612.60
676.50
466.60

Financial Ratios

Consolidated /

Standalone
Description
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Book Value (Rs.)
126.88
101.33
101.43
85.40
67.97
55.66
41.52
33.58
28.75
25.25
ROA
9.37%
5.18%
9.34%
11.11%
12.18%
20.14%
13.93%
10.89%
10.00%
12.35%
ROE
18.30%
11.32%
19.36%
22.26%
23.43%
38.62%
30.85%
26.20%
24.95%
28.64%
ROCE
13.65%
10.02%
15.89%
18.41%
16.50%
28.60%
23.21%
17.67%
18.21%
24.01%
Fixed Asset Turnover
0.89
0.88
1.05
1.38
1.38
1.76
1.80
1.63
1.55
1.58
Receivable days
82.06
97.49
99.21
83.37
76.72
63.29
56.38
51.71
52.78
57.47
Inventory Days
72.81
70.13
70.33
63.69
59.88
54.52
60.13
63.89
64.82
64.85
Payable days
173.43
64.85
68.81
68.11
74.18
65.30
55.05
49.83
43.54
49.87
Cash Conversion Cycle
-18.56
102.77
100.73
78.94
62.42
52.51
61.46
65.78
74.05
72.45
Total Debt/Equity
0.35
0.77
0.76
0.62
0.75
0.43
0.62
0.79
0.99
0.89
Interest Cover
14.54
5.38
13.17
21.87
26.55
40.75
22.29
8.98
5.79
5.35

News Update:


  • Zydus Lifesciences reports 41% fall in Q4 consolidated net profit
    20th May 2022, 16:39 PM

    The company has reported a standalone net profit of Rs 246.90 crore for the quarter ended March 31, 2022

    Read More
  • Zydus Lifesciences launches Bemdac to treat uncontrolled LDL-c
    13th May 2022, 09:10 AM

    Bemdac is an important addition to Zydus’ portfolio of medicines for managing dyslipidemia and cholesterol

    Read More
  • Zydus Lifesciences’ arm gets tentative approval from USFDA for Selexipag Tablets
    6th May 2022, 15:27 PM

    The drug will be manufactured at group’s formulation facility at SEZ, Ahmedabad

    Read More
  • Zydus Lifesciences gets approval from USFDA for Bortezomib for Injection
    4th May 2022, 10:00 AM

    The drug will be manufactured at Zydus Hospira

    Read More
  • Zydus Lifesciences’ ZyCoV-D gets emergency use authorisation from DCGI as two dose vaccine
    26th Apr 2022, 17:41 PM

    With this approval, the vaccine will now be administered on day 0 and day 28

    Read More
  • Zydus Lifesciences gets USFDA’s final approval for Cyanocobalamin Injection
    18th Apr 2022, 10:11 AM

    The group now has 331 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04

    Read More
  • Zydus Lifesciences to manufacture, supply Sagent’s Caffeine Citrate Oral Solution from Gujarat
    13th Apr 2022, 14:30 PM

    The company received the Prior Approval Supplement approval from USFDA, which allows for a site transfer and manufacturing of the drug at Jarod

    Read More
  • Zydus Lifesciences gets PAS approval from USFDA for Mycophenolate Mofetil for Injection
    21st Mar 2022, 09:09 AM

    The injection will be manufactured at the group’s injectables manufacturing facility at Jarod near Vadodara in Gujarat

    Read More
  • Zydus Lifesciences inks pact to acquire 11.86% stake in AMP Energy Green Nine
    17th Mar 2022, 10:20 AM

    This is in line with the company’s the commitment to enhance the share of renewable power source in its operation

    Read More
  • Zydus Lifesciences gets final approval from USFDA for Colestipol Hydrochloride tablets
    14th Mar 2022, 09:13 AM

    The drug will be manufactured at the group’s formulation manufacturing facility at SEZ, Ahmedabad

    Read More
  • USFDA inspects Zydus Lifesciences’ injectable facility in Gujarat
    10th Mar 2022, 15:38 PM

    At the end of the inspection, three observations are issued

    Read More
  • Zydus Lifesciences gets approval from USFDA for Nitroglycerin Sublingual tablets
    9th Mar 2022, 16:15 PM

    Nitroglycerin Sublingual Tablets are used to relieve chest pain (angina) in people who have a certain heart condition

    Read More
  • Zydus Lifesciences’ arm executes asset purchase agreement with BridgeBio
    9th Mar 2022, 09:37 AM

    With the asset purchase of NULIBRY, Zydus Lifesciences aims at bridging unmet healthcare needs of children with rare and orphan paediatric diseases

    Read More
  • Zydus Lifesciences gets DCGI’s approval for Oxemia
    7th Mar 2022, 09:29 AM

    Oxemia is an oral, small molecule hypoxia-inducible factor-prolyl hydroxylase inhibitor

    Read More
  • Zydus Cadila gets USFDA’s final approval for Dapagliflozin Tablets
    23rd Feb 2022, 14:30 PM

    Dapagliflozin is used with a proper diet and exercise program to control high blood sugar in people with type 2 diabetes

    Read More
  • Zydus Cadila’s arm gets USFDA’s final approval for Roflumilast Tablets
    14th Feb 2022, 09:28 AM

    The drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.